Reply To: Traders Market Weekly: Powell Testifies

#60214
Truman
Participant

Biogen (BIIB 315.80, +6.92, +2.2%): late Friday, FDA Advisory Committee votes unanimously to confirm the clinical benefit of LEQEMBI